Skip to main content

Weight Loss-Driven Remission of Prediabetes Tied to Lower Type 2 Diabetes Risk

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

WEDNESDAY, Oct. 11, 2023 -- Weight loss-driven remission of prediabetes protects against type 2 diabetes and is associated with better kidney and vascular function, according to a study published online Sept. 25 in The Lancet Diabetes & Endocrinology.

Arvid Sandforth, M.D., from the University of Tübingen in Germany, and colleagues investigated the mechanisms of weight loss-induced remission in people with prediabetes. The analysis included participants in the Prediabetes Lifestyle Intervention Study (PLIS) and the Diabetes Prevention Program (DPP) study who were randomly assigned to receive a lifestyle intervention or placebo and who lost at least 5 percent of their body weight. Responders were defined as those who returned to normal fasting plasma glucose, normal glucose tolerance, and hemoglobin A1c (HbA1c) <39 mmol/mol after 12 months of lifestyle intervention or placebo or control intervention.

The researchers found that in PLIS, 25.7 percent of participants had weight loss of 5 percent or more of their body weight from baseline, and of these, 43 percent were responders. Among the 683 DPP participants who lost at least 5 percent of their body weight at baseline, 19 percent were responders. While body mass index reduction was similar between responders and nonresponders, whole-body insulin sensitivity increased more in responders than in nonresponders, but insulin secretion did not differ within groups over time or between groups. Intrahepatic lipid content decreased similarly in responders and nonresponders, but visceral adipose tissue decreased more in responders. In the two years after the intervention, responders had a 73 percent lower risk for developing type 2 diabetes than nonresponders.

"We suggest that remission of prediabetes should be the primary therapeutic aim in individuals with prediabetes," the authors write.

Several authors disclosed ties to industry.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted October 2023

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.